Skip to main content

Advertisement

SpringerLink
Log in

Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression

  • Review Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Depression is a complex progressive disorder accompanied by activation of inflammatory and Th-1 driven pathways, oxidative and nitrosative stress (O&NS), lowered antioxidant levels, mitochondrial dysfunctions, neuroprogression and increased bacterial translocation. In depression, activation of immuno-inflammatory pathways is associated with an increased risk for cardio-vascular disorder (CVD). Because of the inflammatory component, the use of cyclooxygenase 2 (COX-2) inhibitors, such as celecoxib, has been advocated to treat depression. Electronic databases, i.e. PUBMED, Scopus and Google Scholar were used as sources for this selective review on the effects of COX-2 inhibitors aggravating the abovementioned pathways. COX-2 inhibitors may induce neuroinflammation, exacerbate Th1 driven responses, increase lipid peroxidation, decrease the levels of key antioxidants, damage mitochondria and aggravate neuroprogression. COX-2 inhibitors may aggravate bacterial translocation and CVD through Th1-driven mechanisms. COX-2 inhibitors may aggravate the pathophysiology of depression. Since Th1 and O&NS pathways are risk factors for CVD, the use of COX-2 inhibitors may further aggravate the increased risk for CVD in depression. Selectively targeting COX-2 may not be a viable therapeutic approach to treat depression. Multi-targeting of the different pathways that play a role in depression is more likely to yield good treatment results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68(21):1800–1808

    Article  PubMed  CAS  Google Scholar 

  • Aid S, Bosetti F (2011) Targeting cyclooxygenases–1 and –2 in neuroinflammation: therapeutic implications. Biochimie 93(1):46–51

    Article  PubMed  CAS  Google Scholar 

  • Aid S, Langenbach R, Bosetti F (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 19(5):17

    Article  Google Scholar 

  • Aid S, Silva AC, Candelario-Jalil E, Choi SH, Rosenberg GA, Bosetti F (2010) Cyclooxygenase–1 and –2 differentially modulate lipopolysaccharide–induced blood–brain barrier disruption through matrix metalloproteinase activity. J Cereb Blood Flow Metab 30(2):370–380

    Article  PubMed  CAS  Google Scholar 

  • Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26(7):607–611

    Article  PubMed  CAS  Google Scholar 

  • Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta–analysis of observational studies. Ann Rheum Dis [Epub ahead of print] PubMed PMID: 22425941

  • Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A (1997) Acute phase proteins in major depression. J Psychosom Res 43(5):529–534

    Article  PubMed  CAS  Google Scholar 

  • Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3):804–817

    Article  PubMed  CAS  Google Scholar 

  • Blais V, Turrin NP, Rivest S (2005) Cyclooxygenase 2 (COX–2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J Neurochem 95(6):1563–1574

    Article  PubMed  CAS  Google Scholar 

  • Bombardier C (2002) An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 89(6A):3D–9D

    Article  PubMed  CAS  Google Scholar 

  • Borgdorff P, Handoko ML, Wong YY, Tangelder GJ (2010) COX–2 inhibition by use of rofecoxib or high dose aspirin enhances ADP–induced platelet aggregation in fresh blood. Open Cardiovasc Med J 4:198–205

    PubMed  CAS  Google Scholar 

  • Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN (2011) ADAPT Research Group. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement 7(4):402–411

    Article  PubMed  Google Scholar 

  • Catena-Dell’Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F, Marazziti D (2011) Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18(2):245–255

    Article  PubMed  Google Scholar 

  • Choi SH, Bosetti F (2009) Cyclooxygenase–1 null mice show reduced neuroinflammation in response to beta–amyloid. Aging (Albany NY) 1(2):234–244

    CAS  Google Scholar 

  • Choi SH, Langenbach R, Bosetti F (2008) Genetic deletion or pharmacological inhibition of cyclooxygenase–1 attenuate lipopolysaccharide–induced inflammatory response and brain injury. FASEB J 22(5):1491–1501

    Article  PubMed  CAS  Google Scholar 

  • de Craen AJ, Gussekloo J, Vrijsen B, Westendorp RG (2005) Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 161(2):114–120

    Article  PubMed  Google Scholar 

  • Dean B, Tawadros N, Scarr E, Gibbons AS (2010) Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 120(1–3):245–248

    Article  PubMed  CAS  Google Scholar 

  • Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67(5):446–457

    Article  PubMed  CAS  Google Scholar 

  • Fields C, Drye L, Vaidya V, Lyketsos C, for the ADAPT Research Group (2011) Celecoxib or Naproxen Treatment Does Not Benefit Depressive Symptoms in Persons Age 70 and Older: Findings From a Randomized Controlled Trial. Am J Geriatr Psychiatry Jul 19 [Epub ahead of print] PubMed PMID: 21775876; PubMed Central PMCID: PMC3209494

  • Firuzi O, Praticò D (2006) Coxibs and Alzheimer’s disease: should they stay or should they go? Ann Neurol 59(2):219–228

    Article  PubMed  CAS  Google Scholar 

  • Gałecki P, Kedziora J, Florkowski A, Gałecka E (2007) Lipid peroxidation and copper-zinc superoxide dismutase activity in patients treated with fluoxetine during the first episode of depression. Psychiatr Pol 41(5):615–624

    PubMed  Google Scholar 

  • Gałecki P, Szemraj J, Bie_kiewicz M, Zboralski K, Gałecka E (2009a) Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 24:277–286

    Article  PubMed  Google Scholar 

  • Gałecki P, Szemraj J, Bie_kiewicz M, Florkowski A, Gałecka E (2009b) Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 61(3):436–447

    PubMed  Google Scholar 

  • Gałecki P, Florkowski A, Bie_kiewicz M, Szemraj J (2010) Functional polymorphism of cyclooxygenase-2 gene (G-765 C) in depressive patients. Neuropsychobiology 62(2):116–120

    Article  PubMed  Google Scholar 

  • Gałecki P, Gałecka E, Maes M, Chamielec M, Orzechowska A, Bobiłska K, Lewiłski A, Szemraj J (2012) The expression of genes encoding for COX–2, MPO, iNOS, and sPLA2–IIA in patients with recurrent depressive disorder. J Affect Disord 138(3):360–366

    Article  PubMed  Google Scholar 

  • Gardner A, Boles RG (2011) Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 35(3):730–743

    Article  PubMed  CAS  Google Scholar 

  • Gilroy DW, Stables M, Newson J (2010) In vivo models to study cyclooxygenase products in health and disease: introduction to Part III. Methods Mol Biol 644:181–188

    Article  PubMed  CAS  Google Scholar 

  • Grosser T (2006) The pharmacology of selective inhibition of COX–2. Thromb Haemost 96(4):393–400

    PubMed  CAS  Google Scholar 

  • Grosser T, Yu Y, Fitzgerald GA (2010) Emotion recollected in tranquility: lessons learned from the COX–2 saga. Annu Rev Med 61:17–33

    Article  PubMed  CAS  Google Scholar 

  • Gu XL, Long CX, Sun L, Xie C, Lin X, Cai H (2010) Astrocytic expression of Parkinson’s disease–related A53T alpha–synuclein causes neurodegeneration in mice. Mol Brain 3:12

    Article  PubMed  Google Scholar 

  • Gupta S, Sarotra P, Aggarwal R, Dutta N, Agnihotri N (2007) Role of oxidative stress in celecoxib–induced renal damage in wistar rats. Dig Dis Sci 52(11):3092–3098

    Article  PubMed  CAS  Google Scholar 

  • Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C–reactive protein, IL–1, and IL–6: a meta–analysis. Psychosom Med 71(2):171–186

    Article  PubMed  CAS  Google Scholar 

  • Huntjens DR, Strougo A, Chain A, Metcalf A, Summerfield S, Spalding DJ, Danhof M, Della Pasqua O (2008) Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. Br J Pharmacol 153(5):1072–1084

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996) COX–2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93(6):2317–2321

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann WE, Andreasson KI, Isakson PC, Worley PF (1997) Cyclooxygenases and the central nervous system. Prostaglandins 54(3):601–624

    Article  PubMed  CAS  Google Scholar 

  • Kessing LV, Andersen PK (2004) Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 75(12):1662–1666

    Article  PubMed  CAS  Google Scholar 

  • Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress–induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):744–759

    Article  PubMed  CAS  Google Scholar 

  • Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE (2005) Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Abeta42 production. Nat Med 11(5):545–550

    Article  PubMed  CAS  Google Scholar 

  • Leonard B, Maes M (2012) Mechanistic explanations how cell–mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36(2):764–785

    Article  PubMed  CAS  Google Scholar 

  • Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM, Xu H, Xia N, Kleschyov AL, Mang C, Warnholtz A, Münzel T, Förstermann U (2008) Cyclooxygenase 2–selective and nonselective nonsteroidal anti–inflammatory drugs induce oxidative stress by up–regulating vascular NADPH oxidases. J Pharmacol Exp Ther 326(3):745–753

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, Ho RC, Mak A (2011) Interleukin (IL)–6, tumour necrosis factor alpha (TNF–α) and soluble interleukin–2 receptors (sIL–2R) are elevated in patients with major depressive disorder: A meta–analysis and meta–regression. J Affect Disord 2011 Aug 25. [Epub ahead of print] PubMed PMID: 21872339

  • López-Villodres JA, De La Cruz JP, Muñoz-Marin J, Guerrero A, Reyes JJ, González-Correa JA (2012) Cytoprotective effect of nonsteroidal antiinflammatory drugs in rat brain slices subjected to reoxygenation after oxygen–glucose deprivation. Eur J Pharm Sci 45(5):624–631

    Article  PubMed  Google Scholar 

  • MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, Nahmias C, Young LT (2003) Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100(3):1387–1392

    Article  PubMed  CAS  Google Scholar 

  • Maes M (1993) A review on the acute phase response in major depression. Rev Neurosci 4(4):407–416

    PubMed  CAS  Google Scholar 

  • Maes M (2008) The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 29(3):287–291

    PubMed  CAS  Google Scholar 

  • Maes M (2011) Depression is an inflammatory disease, but cell–mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):664–675

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990) Immune disturbances during major depression: upregulated expression of interleukin–2 receptors. Neuropsychobiology 24(3):115–120

    Article  PubMed  Google Scholar 

  • Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J (1991) Depression–related disturbances in mitogen–induced lymphocyte responses and interleukin–1 beta and soluble interleukin–2 receptor production. Acta Psychiatr Scand 84(4):379–386

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B, Raus J (1992a) Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 22(1):45–53

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Scharpé S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy E (1992b) Higher alpha 1–antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord 24(3):183–192

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Stevens WJ, Declerck LS, Bridts CH, Peeters D, Schotte C, Cosyns P (1993) Significantly increased expression of T–cell activation markers (interleukin–2 and HLA–DR) in depression: further evidence for an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 17(2):241–255

    Article  PubMed  CAS  Google Scholar 

  • Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A (2000) Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 58(3):241–246

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Kubera M, Leunis JC (2008) The gut–brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 29(1):117–124

    PubMed  Google Scholar 

  • Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1):27–53

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Gałecki P, Chang YS, Berk M (2011a) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35(3):676–692

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J (2011b) Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 32(1):7–24

    PubMed  CAS  Google Scholar 

  • Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011c) IgM–mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1–3):414–418

    Article  PubMed  CAS  Google Scholar 

  • Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2011d) Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis / chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett 32(2):133–140

    PubMed  Google Scholar 

  • Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012a) New drug targets in depression: inflammatory, cell–mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK–3 inhibitors. Inflammopharmacology 2012 Jan 24. [Epub ahead of print] PubMed PMID: 22271002

  • Maes M, Kubera M, Leunis JC, Berk M (2012b) Increased IgA and IgM responses against gut commensals in chronic depression: Further evidence for increased bacterial translocation or leaky gut. J Affect Disord Mar 11. [Epub ahead of print] PubMed PMID: 22410503

  • Maes M, Mihaylova I, Kubera M, Ringel K (2012c) Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry 36(1):169–175

    Article  PubMed  Google Scholar 

  • Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA (2004) The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase–-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 10(4):352–356

    Article  PubMed  Google Scholar 

  • Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M (2001) Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 11(3):203–208

    Article  PubMed  CAS  Google Scholar 

  • Minghetti L (2004) Cyclooxygenase–2 (COX–2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63(9):901–910

    PubMed  CAS  Google Scholar 

  • Minghetti L (2007) Role of COX–2 in inflammatory and degenerative brain diseases. Subcell Biochem 42:127–141

    Article  PubMed  Google Scholar 

  • Montrose DC, Kadaveru K, Ilsley JN, Root SH, Rajan TV, Ramesh M, Nichols FC, Liang BT, Sonin D, Hand AR, Zarini S, Murphy RC, Belinsky GS, Nakanishi M, Rosenberg DW (2010) cPLA2 is protective against COX inhibitor–induced intestinal damage. Toxicol Sci 117(1):122–132

    Article  PubMed  CAS  Google Scholar 

  • Morita I (2002) Distinct functions of COX–1 and COX–2. Prostaglandins Other Lipid Mediat 68–69:165–175

    Article  PubMed  Google Scholar 

  • Moylan S, Maes M, Wray NR, Berk M (2012) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry in press

  • Müller N (2010) COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11(1):31–42

    PubMed  Google Scholar 

  • Müller N, Schwarz MJ (2008) COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 14(14):1452–1465

    Article  PubMed  Google Scholar 

  • Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double–blind, randomized, placebo controlled, add–on pilot study to reboxetine. Mol Psychiatry 11(7):680–684

    Article  PubMed  Google Scholar 

  • Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE (2007) Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 14(2):65–71

    Article  PubMed  CAS  Google Scholar 

  • Nowak G, Szewczyk B, Pilc A (2005) Zinc and depression. An update. Pharmacol Rep 57(6):713–718

    PubMed  CAS  Google Scholar 

  • Padol IT, Hunt RH (2010) Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology (Oxford) 49(5):837–843

    Article  CAS  Google Scholar 

  • Reuben SS, Steinberg R (1999) Gastric perforation associated with the use of celecoxib. Anesthesiology 91(5):1548–1549

    Article  PubMed  CAS  Google Scholar 

  • Salinas G, Rangasetty UC, Uretsky BF, Birnbaum Y (2007) The cycloxygenase 2 (COX-2) story: it’s time to explain, not inflame. J Cardiovasc Pharmacol Ther 12(2):98–111

    Article  PubMed  CAS  Google Scholar 

  • Scott KF, Bryant KJ, Bidgood MJ (1999) Functional coupling and differential regulation of the phospholipase A2–cyclooxygenase pathways in inflammation. J Leukoc Biol 66(4):535–541

    PubMed  CAS  Google Scholar 

  • Sharma B, Singh N, Singh M (2008) Modulation of celecoxib–and streptozotocin–induced experimental dementia of Alzheimer’s disease by pitavastatin and donepezil. J Psychopharmacol 22(2):162–171

    Article  PubMed  CAS  Google Scholar 

  • Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10):1247–1255

    Article  PubMed  CAS  Google Scholar 

  • Singh VP, Patil CS, Jain NK, Kulkarni SK (2004) Aggravation of inflammatory bowel disease by cyclooxygenase–2 inhibitors in rats. Pharmacology 72(2):77–84

    Article  PubMed  CAS  Google Scholar 

  • Smecuol E, Bai JC, Sugai E, Vazquez H, Niveloni S, Pedreira S, Mauriño E, Meddings J (2001) Acute gastrointestinal permeability responses to different non–steroidal anti–inflammatory drugs. Gut 49(5):650–655

    Article  PubMed  CAS  Google Scholar 

  • Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I (1997) Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut 41(3):344–353

    Article  PubMed  CAS  Google Scholar 

  • Somasundaram S, Sigthorsson G, Simpson RJ, Watts J, Jacob M, Tavares IA, Rafi S, Roseth A, Foster R, Price AB, Wrigglesworth JM, Bjarnason I (2000) Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID–enteropathy in the rat. Aliment Pharmacol Ther 14(5):639–650

    Article  PubMed  CAS  Google Scholar 

  • Song C, Wang H (2011) Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):760–768

    Article  PubMed  CAS  Google Scholar 

  • Sozer S, Diniz G, Lermioglu F (2011) Effects of celecoxib in young rats: histopathological changes in tissues and alterations of oxidative stress/antioxidant defense system. Arch Pharm Res 34(2):253–259

    Article  PubMed  CAS  Google Scholar 

  • Suddek GM, El-Kenawi AE, Abdel-Aziz A, El-Kashef HA (2011) Celecoxib, a selective cyclooxygenase–2 inhibitor, attenuates renal injury in a rat model of Cisplatin–induced nephrotoxicity. Chemotherapy 57(4):321–326

    Article  PubMed  CAS  Google Scholar 

  • Takahashi T, Zhu SJ, Sumino H, Saegusa S, Nakahashi T, Iwai K, Morimoto S, Kanda T (2005) Inhibition of cyclooxygenase–2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci 78(2):195–204

    Article  PubMed  CAS  Google Scholar 

  • Thiéfin G, Beaugerie L (2005) Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 72(4):286–294

    Article  PubMed  Google Scholar 

  • Villegas I, Martín MJ, La Casa C, Motilva V, De La Lastra CA (2002) Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study. Free Radic Res 36(7):769–777

    Article  PubMed  CAS  Google Scholar 

  • Wang D, Dubois RN (2005) Prostaglandins and cancer. Gut 55(1):115–122

    Article  PubMed  Google Scholar 

  • Whittle BJ (2004) Mechanisms underlying intestinal injury induced by anti–inflammatory COX inhibitors. Eur J Pharmacol 500(1–3):427–439

    Article  PubMed  CAS  Google Scholar 

  • Zwolinska-Wcislo M, Krzysiek-Maczka G, Ptak-Belowska A, Karczewska E, Pajdo R, Sliwowski Z, Urbanczyk K, Drozdowicz D, Konturek SJ, Pawlik WW, Brzozowski T (2011) Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. J Physiol Pharmacol 62(3):357–368

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The author declares that he has no conflict of interest.

Author information

Authors and Affiliations

  1. Maes Clinics @ TRIA, Piyavate Hospital 998 Rimklongsamsen Road, Bangkok, 10310, Thailand

    Michael Maes

Authors
  1. Michael Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Maes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maes, M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 27, 405–413 (2012). https://doi.org/10.1007/s11011-012-9326-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-012-9326-6

Keywords

Search

Navigation